Nelson Peltz
Trian Fund Management
Nelson Peltz Chemours Co stake
total: 34
Trian Fund Management CC trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2015 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2015 Q4
According to 2026 Q2 report, Nelson Peltz doesn't hold any Chemours Co (CC) shares. To date, the estimated cost basis is nearly $6.47 for "buy" trades and estimated average "sell" price is $6.47. Trian Fund Management first purchased CC in 2015 Q3, initially acquiring about 4.88M shares. Since the initial investment in Chemours Co (CC), Trian Fund Management has made 1 more transaction.
When did Nelson Peltz sell Chemours Co (CC)?
Nelson Peltz sold off the entire Chemours Co (CC) position in 2015 Q4.
When did Nelson Peltz buy Chemours Co (CC)?
Nelson Peltz first invested in Chemours Co (CC) in 2015 Q3 at the reported quarter-end price of $6.47 per share.
What's the cost basis of Trian Fund Management's CC stake?
The estimated cost basis for Chemours Co (CC) stake is around $6.47 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $6.47
- Weighted AVG sell price:
- $6.47
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.